Overview Request Sample Pages Request Customization Download PDF
You are viewing: US Chemiluminescence Immunoassay Market analysis

The US Chemiluminescence Immunoassay Market was valued at $3362.8 Million in 2026 and projected to reach to $4875.9 Million by 2031, representing a compound annual growth rate of 7.7%. The US chemiluminescence immunoassay market is positioned for sustained growth through 2031, driven by technological advancements in automated diagnostic platforms and increasing healthcare expenditure.

US Chemiluminescence Immunoassay Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

US Chemiluminescence Immunoassay Market Trends and Insights

  • The US market benefits from advanced healthcare infrastructure, high diagnostic spending, and widespread adoption of automated immunoassay platforms across clinical laboratories and hospitals.
  • Increasing prevalence of chronic diseases and demand for rapid, accurate diagnostic testing continue to drive market expansion throughout the US. In the US, chemiluminescence immunoassay technology remains the preferred choice for hormone, tumor marker, and infectious disease testing due to superior sensitivity and specificity.
  • The US market is characterized by strong competition among established diagnostic manufacturers and growing investment in point-of-care testing solutions.
  • Between 2026 and 2031, the US is expected to see accelerated adoption driven by healthcare consolidation, reimbursement improvements, and integration of artificial intelligence in diagnostic workflows..

Key Market Statistics

  • CAGR (2026-2031) 7.7% CAGR
  • Market Size, 2026 ~USD 3362.8 Million
  • Forecast, 2031 ~USD 4875.9 Million
  • Country US

US Chemiluminescence Immunoassay Market Overview

Market Valuation Growth :

The US chemiluminescence immunoassay market is valued at $3,362.8 million in 2026 and is projected to reach $4,875.9 million by 2031, demonstrating robust expansion driven by increasing diagnostic demand across American healthcare facilities.

Strong CAGR Performance :

The US market is growing at a 7.7% CAGR from 2026-2031, outpacing the global growth rate of 7.2%, indicating accelerating adoption of chemiluminescence immunoassay technologies within the American healthcare system.

Advanced Healthcare Infrastructure :

The US benefits from state-of-the-art diagnostic infrastructure, high healthcare spending per capita, and widespread integration of automated immunoassay platforms across clinical laboratories, hospitals, and diagnostic centers nationwide.

Rising Disease Prevalence :

Increasing prevalence of chronic diseases, infectious diseases, and cancer in the US population is driving demand for accurate and rapid diagnostic testing, fueling adoption of chemiluminescence immunoassay technologies in clinical settings.

US Chemiluminescence Immunoassay Market Dynamics

  • Clinical laboratories and hospitals are increasingly adopting these systems to improve diagnostic accuracy and operational efficiency.
  • The market will benefit from rising disease prevalence, aging demographics, and growing demand for point-of-care testing solutions across American healthcare facilities. Key growth drivers include regulatory support for advanced diagnostic technologies, integration of artificial intelligence in immunoassay systems, and expansion of testing capabilities in smaller healthcare facilities.
  • Investment in healthcare infrastructure modernization and the shift toward personalized medicine will further accelerate market expansion.
  • The competitive landscape will intensify as manufacturers focus on developing cost-effective, high-throughput solutions tailored to the US market's specific clinical and operational requirements..

Related Ecosystem

Medical Devices

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Magnetic Resonance Imaging (MRI)
  • Disposable Autoinjectors
  • Pulse Oximeters
  • Blood Pressure Monitors
Top Companies
  • Medtronic plc
  • Abbott Laboratories
  • Stryker Corporation
  • Becton, Dickinson and Company
  • CONMED Corporation

    Key Takeaways

    • The US chemiluminescence immunoassay market will grow from $3,362.8M (2026) to $4,875.9M (2031) at a 7.7% CAGR.
    • The US market is driven by advanced laboratory infrastructure, high diagnostic spending, and automation adoption in clinical settings.
    • The US shows strong demand for hormone and tumor marker testing, positioning chemiluminescence as the gold standard technology.
    • The US market will benefit from AI integration, healthcare consolidation, and improved reimbursement policies through 2031.

    Chemiluminescence Immunoassay Market Report Scope

    Report Metric Details
    Base Year 2026
    Fastest Growing Segment ONCOLOGY (Application)
    Forecast Period 2026–2031
    Growth Rate CAGR of 7.2% from 2026 to 2031
    Largest Segment CONSUMABLES (Product Type)
    Market Size Base Year (Billions) ~USD 11.58 (2026)
    Revenue Forecast (Billions) ~USD 16.39 (2031)
    Segments Covered Product Type, Technology, Sample Type, Application, End User

    US Chemiluminescence Immunoassay Market Report Segmentation

    5 segment dimensions are covered across the global market.

    By Product Type

    • Consumables
    • Instruments

    By Technology

    • Chemiluminescence Enzyme Immunoassays (Cleia)
    • Electrochemiluminescence Immunoassays (Ecli)
    • Microparticle Chemiluminescence Immunoassays

    By Sample Type

    • Blood
    • Other Sample Types
    • Saliva
    • Urine

    By Application

    • Allergy Diagnostics
    • Autoimmune Disorders
    • Blood Screening
    • Bone & Mineral Disorders
    • Cardiology
    • Endocrinology
    • Gastroenterology
    • Infectious Diseases
    • Metabolic Disorders
    • Neurology
    • Newborn Screening
    • Oncology
    • Other Applications
    • Respiratory Diseases
    • Therapeutic Drug Monitoring
    • Toxicology

    By End User

    • Clinical Laboratories
    • Hospitals
    • Other End Users
    • Pharmaceutical & Biotechnology Companies And Cros

    US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2024–2031

    Segment20242025202620272028202920302031CAGR (%)
    CLINICAL LABORATORIES1116.61184.31260.91345.81439.71544.71661.11790.77.3
    HOSPITALS1759.21872.42000.42142.52299.92476.12671.92890.47.6
    OTHER END USERS378.1398.1420.7445.7473.2504537.9575.66.5
    PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS364.5385.4409435.1464496.2531.9571.66.9
    TOTAL3618.43840.24090.94369.14676.750215402.95828.37.3

    Target Audience

    • Diagnostic Equipment Manufacturers : Need detailed US market insights to develop competitive immunoassay platforms, optimize product portfolios, and identify expansion opportunities within American clinical laboratories and hospital networks.
    • Clinical Laboratory Operators : Require market data to evaluate automation investments, benchmark operational efficiency against industry standards, and make informed purchasing decisions for chemiluminescence immunoassay systems.
    • Healthcare Investment Firms : Seek comprehensive US market analysis to identify investment opportunities, assess portfolio company performance, and evaluate acquisition targets within the growing American diagnostic testing sector.
    • Hospital & Healthcare System Administrators : Need market forecasts and technology trends to plan capital expenditures, upgrade diagnostic capabilities, and align laboratory infrastructure with evolving clinical demands across US healthcare facilities.
    • Regulatory & Policy Advisors : Require US-specific market data to inform healthcare policy recommendations, assess diagnostic technology adoption rates, and understand reimbursement implications for chemiluminescence immunoassay services.

    Key Companies in the US Chemiluminescence Immunoassay Market

    CompanyHQOwnershipStrongest segments
    ABBOTTUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
    SIEMENS HEALTHINEERS AGGermanyPublic CompanyImaging,Diagnostics,Varian (Oncology),
    DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology (bioprocessing and bioproduction solutions),Life Sciences (instruments, genomics, and research tools),Diagnostics (clinical instruments and consumables),
    DIASORIN S.P.A.ItalyPublic CompanyLIAISON XL / LIAISON XS immunodiagnostics,Molecular diagnostics (Simplexa, congenital CMV, LIAISON PLEX assays),xMAP technology platform and related IVD solutions,
    QUIDELORTHO CORPORATIONUnited StatesPublic CompanyLabs (clinical chemistry and immunoassay),Point of Care,Transfusion Medicine,
    SYSMEX CORPORATIONJapanPublic CompanyHematology analyzers & reagents (XN-Series, XN-V, ProCyte Dx),Coagulation systems & reagents,Blood gas / electrolyte / urinalysis,
    SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.ChinaPublic CompanyImmunoassay analyzers and reagents,Biochemistry/Electrolyte systems and reagents,Integrated systems and lab automation,
    TOSOH CORPORATIONJapanPublic CompanyBasic chemicals and chlor-alkali (caustic soda, sodium bicarbonate, related),Vinyls, PVC chain, and petrochemicals (VCM, ethylene, propylene, aromatics),Advanced materials (battery materials, quartzware, silica glass, thin films, zeolites, zirconia, beads),
    BIO-RAD LABORATORIES, INC.United StatesPublic CompanyClinical Diagnostics,Life Science Research Instruments and Consumables,Informatics and Software,
    SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.ChinaPublic CompanyPatient monitoring & life support (incl. ventilators, anesthesia, defibrillation, infusion),Ultrasound & medical imaging (incl. radiology, emergency ultrasound, endoscope camera systems),In-vitro diagnostics (CLIA, chemistry, hematology),

    ABBOTT

    Abbott is a United States-based public company founded in 1888 with 115,000 employees, operating in the healthcare and pharmaceutical sectors.

    SIEMENS HEALTHINEERS AG

    Siemens Healthineers AG is a German public company founded in 1896 with 72,369 employees, specializing in medical technology and diagnostics.

    DANAHER CORPORATION

    Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees operating across diversified industrial and life sciences sectors.

    DIASORIN S.P.A.

    DiaSorin S.p.A. is an Italian public company founded in 1968 with 3,242 employees engaged in in vitro diagnostics and molecular diagnostics.

    QUIDELORTHO CORPORATION

    QuidelOrtho Corporation is a United States-based public company founded in 1979 with 6,500 employees specializing in diagnostic solutions.

    SYSMEX CORPORATION

    Sysmex Corporation is a Japanese public company founded in 1968 with 10,861 employees focused on in vitro diagnostics and hematology systems.

    SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.

    Shenzhen New Industries Biomedical Engineering Co., Ltd. is a Chinese public company founded in 1995 with 2,785 employees operating in the biomedical diagnostics sector.

    TOSOH CORPORATION

    Tosoh Corporation is a Japanese public company founded in 1935 with 14,850 employees engaged in specialty chemicals and diagnostics.

    BIO-RAD LABORATORIES, INC.

    Bio-Rad Laboratories, Inc. is a United States-based public company founded in 1952 with 7,450 employees providing life science research and clinical diagnostics products.

    SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.

    Shenzhen Mindray Bio-Medical Electronics Co., Ltd. is a Chinese public company founded in 1991 with 21,288 employees manufacturing medical devices and diagnostics equipment.

    Reasons to Buy this Report

    • Market Size & Growth Validation : Obtain precise valuation data for the US market ($3.36B in 2026) with detailed 5-year forecasts through 2031, enabling accurate financial planning and investment decisions for diagnostic companies and healthcare providers.
    • Competitive Positioning Intelligence : Understand the US-specific competitive landscape, market dynamics, and technology adoption rates to identify opportunities for market entry, expansion, or product differentiation within American clinical laboratories and hospitals.
    • Strategic Growth Opportunities : Identify high-growth segments within the US market driven by disease prevalence, automation adoption, and healthcare infrastructure modernization to prioritize resource allocation and develop targeted go-to-market strategies.
    • Regulatory & Compliance Insights : Access US-specific regulatory requirements, reimbursement trends, and compliance considerations essential for launching or scaling chemiluminescence immunoassay products in American healthcare settings.
    • Investment & Partnership Decisions : Make informed decisions on acquisitions, partnerships, and capital investments in the US diagnostic market with comprehensive data on market trends, growth drivers, and emerging opportunities through 2031.

    Frequently asked questions

    What is the current size of the US chemiluminescence immunoassay market?

    The US chemiluminescence immunoassay market is estimated at $3,362.8 million in 2026 and is expected to reach $4,875.9 million by 2031.

    What is the projected growth rate for the US market?

    The US chemiluminescence immunoassay market is projected to grow at a compound annual growth rate (CAGR) of 7.7% from 2026 to 2031.

    What factors are driving growth in the US market?

    Key drivers in the US include advanced healthcare infrastructure, high diagnostic spending, automation in clinical laboratories, rising chronic disease prevalence, and increasing demand for rapid diagnostic testing.

    Which applications dominate the US chemiluminescence immunoassay market?

    The US market is dominated by hormone testing, tumor marker detection, and infectious disease diagnostics, where chemiluminescence technology offers superior sensitivity and specificity.

    What trends will shape the US market through 2031?

    Key trends in the US include AI integration in diagnostic workflows, healthcare system consolidation, point-of-care testing expansion, and improved reimbursement policies for immunoassay testing.

    RESEARCH METHODOLOGY

    This study involved four major activities in estimating the size of the CLIA market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.

    Secondary Research

    The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and companies' SEC filings. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the CLIA market. It was also used to obtain important information on key players, market classification, and segmentation aligned with industry trends to the bottom-most level, and key developments from market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

    Primary Research

    Extensive primary research was conducted after secondary research provided information on the CLIA market. Several primary interviews were conducted with market experts from both the demand and supply sides across major countries of North America, Europe, Asia Pacific,  Latin America, and the Middle East & Africa. Primary data was collected through questionnaires, emails, and telephonic interviews. The primary sources from the supply side included various industry experts, such as Chief Executive Officers (CXOs), Vice Presidents (VPs), Directors from business development, marketing, and product development/innovation teams, as well as related key executives from manufacturers and distributors operating in the CLIA market.; and key opinion leaders.

    Primary interviews were conducted to gather insights into market statistics, revenue from products and services, market breakdowns, market size estimates, market forecasting, and data triangulation. Primary research also helped in understanding the various trends in technology, applications, verticals, and regions. Stakeholders from the demand side, customers/end users who are using infection control products, were interviewed to understand the buyer’s perspective on the suppliers, products, and their current usage and the future outlook of their business, which will affect the overall market.

    The following is a breakdown of the primary respondents:

    Chemiluminescence Immunoassay Market Size, and Share

    Note 1: C-level primaries include CEOs, COOs, CTOs, and VPs.
    Note 2: Other primaries include sales managers, marketing managers, and product managers.
    Note 3: Companies are classified into tiers based on their total revenue.
    As of 2023: Tier 1=>USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, Tier 3=<USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The research methodology used to estimate the size of the CLIA market includes the following details.

    The market sizing was conducted on a global basis.

    Country-level Analysis: The size of the CLIA market was obtained from the annual presentations of leading players and secondary data available in the public domain. The share of products in the overall CLIA market was obtained from secondary data and validated by primary participants to arrive at the total CLIA market. Primary participants further validated the numbers.

    Geographic market assessment (by region & country): The geographic assessment was done using the following approaches:

    Approach 1: Geographic revenue contributions/splits of leading players in the market (wherever available) and respective growth trends
    Approach 2: Geographic adoption trends for individual product segments by end user and growth prospects for each of the segments (assumptions and indicative estimates validated from primary interviews)

    At each point, the assumptions and approaches were validated through industry experts contacted during primary research. Considering the limitations of data available from secondary research, revenue estimates for individual companies (for the overall CLIA market and geographic market assessment) were ascertained based on a detailed analysis of their respective product offerings, geographic reach/strength (direct or through distributors or suppliers), and the shares of the leading players in a particular region or country.

    Global Chemiluminescence Immunoassay Market : Top-Down and Bottom-Up Approach

    Chemiluminescence Immunoassay Market Top Down and Bottom Up Approach

    Data Triangulation

    The market was split into several segments and subsegments after determining the overall market size, using the market sizing processes. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and determine the exact statistics for each market segment and subsegment. The data was triangulated by examining various factors and trends on both the demand and supply sides of the CLIA market.

    Market Definition

    Chemiluminescent immunoassay (CLIA) is an immunoassay technique in which the label, i.e., the indicator of the analytical reaction, is a luminescent molecule. CLIA is a variation of the standard enzyme immunoassay (EIA), a biochemical technique used in immunology. This variation technique can be used for medical diagnosis and in several other industries for various applications. In recent years, CLIA has attracted increasing attention across fields such as clinical diagnosis, life sciences, food safety, environmental monitoring, and pharmaceutical analysis, due to its high specificity, high sensitivity, broad applicability, simple instrumentation, and wide linear range.

    Key Stakeholders

    • CLIA manufacturers and distributors
    • CLIA analyzers & consumables manufacturers
    • Healthcare institutions (hospitals, medical schools, group practices, individual surgeons, and governing bodies)
    • Healthcare institutions (hospitals and outpatient clinics)
    • Distributors and suppliers
    • Research institutes
    • Health insurance payers
    • World Health Organization (WHO)
    • Organisation for Economic Co-operation and Development (OECD)
    • National Institutes of Health (NIH)
    • Centers for Disease Control and Prevention (CDC)
    • Annual Reports/SEC Filings, Investor Presentations, and Press Releases of Key Players
    • White Papers, Journals/Magazines, and News Articles
    • Paid Databases, such as Factiva, D&B Hoovers, and Bloomberg Business

    Report Objectives

    • To define, describe, segment, and forecast the global CLIA market by product type, technology, sample type, application, end user, and region.
    • To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall CLIA market.
    • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.
    • To forecast the size of the CLIA market in five main regions, along with their respective key countries, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
    • To profile key players in the global CLIA market and comprehensively analyze their core competencies and market shares.
    • To track and analyze competitive developments such as acquisitions, expansions, partnerships, agreements, and collaborations; and product launches and approvals.
    • To benchmark players within the CLIA market using the "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy.

    Available customizations:

    Based on the given market data, MarketsandMarkets offers customizations tailored to the company’s specific needs. The following customization options are available for the report:

    Geographic Analysis

    • Further breakdown of the Rest of Asia Pacific CLIA market into Thailand, Indonesia, Philippines, Vietnam, Hong Kong, and other countries
    • Further breakdown of the Rest of Europe CLIA market into Belgium, Russia, the Netherlands, Switzerland, and other countries.
    • Further breakdown of the Rest of Latin America CLIA market into Argentina, Peru, and other countries.

     

    Get the Full Chemiluminescence Immunoassay Market Report

    Full forecast, segment splits, and company analysis for all Chemiluminescence Immunoassay Market.

    Download Sample Pages Buy Report

    METHODOLOGY

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    Cite this Research
    DMCA.com Protection Status